In conclusion, our research indicates that miR-34c could inhibit osteogenic differentiation and calcification of VICs by targeting STC1 to suppress JNK signaling pathway (Figure 6), hence providing a potential therapeutic target for the CAVD. This evidence concerns the gene STC1 and congenital bilateral aplasia of vas deferens from CFTR mutation.